<DOC>
	<DOC>NCT00845988</DOC>
	<brief_summary>The primary goal of this study is to investigate metabolic changes and maintaining efficacy in stabilized patients with bipolar disorders who have pharmacologically induced weight gain.</brief_summary>
	<brief_title>Metabolic Effects of Switching to Aripiprazole in Patients With Bipolar Disorders</brief_title>
	<detailed_description>- reduced treatment adherence due to metabolic side effects - suggested advantages of aripiprazole in metabolic profile over other antipsychotics or mood stabilizers - randomized trial of switch from previous drugs to aripiprazole</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>patients with bipolar disorders (I, II, NOS) diagnosed with DSMIV criteria age between 18 and 65 Decisional capacity is adequate to provide informed consent or has an authorized appropriate surrogate decision maker. in a syndromal remission state at least for 2 months : CGI BP â‰¤ 3 patients who have exhibited a clinically significant increase in body weight after starting the administration of their current antipsychotic (ie &gt;7% weight gain) diagnosis of eating disorder, substance abuse, and psychotic disorder history of neurological and medical illness pregnant or breast feeding women</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Bipolar disorder</keyword>
	<keyword>metabolic complication</keyword>
	<keyword>Aripiprazole</keyword>
	<keyword>Weight gain</keyword>
	<keyword>Clinical Trial</keyword>
	<keyword>Antipsychotic</keyword>
	<keyword>Metabolic syndrome</keyword>
	<keyword>Psychopharmacology</keyword>
	<keyword>Open Label</keyword>
</DOC>